Total Funding
95
60
Total FundingPost-IPO Debt raised
Growth Score
41 pts
Heat Score
13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
10892
Apollomics is a biopharmaceutical company discovering and developing mono- and combination- oncology therapies to harness the immune system.
- Qian Shi: China General Manager and Head of SciencePast Role: Apollomics, China General Manager and Head of Science
- Matthew Plunkett: Chief Financial OfficerPast Role: iPierian, Vice President and Chief Financial Officer
About the Company
Apollomics is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including the novel, humanized monoclonal
antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.
